Preclinical research has shown that FAK inhibition can lead to decreased levels of fibrosis, synergy with chemotherapy and ICIs, and improved survival outcomes in the KPC mouse model of pancreatic cancer.254 Currently, a number of clinical trials to investigate the efficacy of combinations of FAK inhibitors and ICIs and/or cytotoxic agents or MEK inhibitors are ongoing (NCT02546531, NCT02758587, NCT02428270). The gene discussed is MAP2K7; the disease is pancreatic neoplasm.